Ludwig Enterprises Announces Executive and Director Changes
Ticker: LUDG · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1960262
| Field | Detail |
|---|---|
| Company | Ludwig Enterprises, Inc. (LUDG) |
| Form Type | 8-K |
| Filed Date | Sep 8, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
TL;DR
Ludwig Enterprises shakes up leadership and exec pay - new board members in, some execs out.
AI Summary
Ludwig Enterprises, Inc. announced on September 5, 2025, changes in its executive and director roles. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key executives. Specific names and financial details of these changes were not provided in this initial filing.
Why It Matters
Changes in leadership and executive compensation can signal shifts in company strategy, operational focus, or financial performance, impacting investor confidence and stock valuation.
Risk Assessment
Risk Level: medium — Executive and director changes can introduce uncertainty about future strategy and performance, potentially increasing risk.
Key Players & Entities
- Ludwig Enterprises, Inc. (company) — Registrant
- Nevada (jurisdiction) — State of incorporation
- September 5, 2025 (date) — Date of earliest event reported
FAQ
What specific roles have been affected by the departures and appointments at Ludwig Enterprises?
The filing indicates the departure of certain officers and directors, the election of new directors, and changes to compensatory arrangements for certain officers, but does not specify the exact roles affected in this report.
When did the events reported in this 8-K filing occur?
The earliest event reported occurred on September 5, 2025.
What is the principal executive office address for Ludwig Enterprises?
The principal executive offices are located at 8950 SW 74th Ct Ste 2201-A149, Miami, FL 33156.
What is the IRS Employer Identification Number for Ludwig Enterprises?
The IRS Employer Identification Number is 61-1133438.
What is the SIC code for Ludwig Enterprises?
The Standard Industrial Classification code is 8071, which corresponds to SERVICES-MEDICAL LABORATORIES.
Filing Stats: 828 words · 3 min read · ~3 pages · Grade level 12.1 · Accepted 2025-09-08 16:01:36
Filing Documents
- ea0256415-8k_ludwig.htm (8-K) — 27KB
- 0001213900-25-085512.txt ( ) — 186KB
- ludg-20250905.xsd (EX-101.SCH) — 3KB
- ludg-20250905_lab.xml (EX-101.LAB) — 33KB
- ludg-20250905_pre.xml (EX-101.PRE) — 22KB
- ea0256415-8k_ludwig_htm.xml (XML) — 3KB
02 Departure of Directors or Certain
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 5, 2025, Corain McGinn was appointed as Independent Director to Ludwig Enterprises, Inc. (the "Company") Board of Directors, effective immediately. Mr. McGinn is being appointed to the Board of Directors to fill the vacancies created on the Board of the Company. Mr. McGinn, age 56, is an experienced and effective executive with many years working around the globe with both Fortune 100 and emerging companies in technology, pharmaceutical and biotechnology. His focus is on bringing comprehensive and creative solutions that drive impact and revenue. He has worked at the executive level of, for example, Advanced Micro Devices Inc., Microsoft Corp, Merck & Co. (including Merck Research Labs, Merck Latin America, Merck Australia), Novartis AG, Schering-Plough Corporation, Hitachi Ltd. (including Hitachi Data Systems, Hitachi Industrial, and Hitachi Medical), in addition to hundreds of less well known but market leading and innovative companies His work has ranged from providing high-level strategic vision and priorities to drive and create markets; to developing multi-year strategic plans for the use of information technology to improve the pharma research and development process from compound discovery through final clinical trials and FDA approval; and, to designing competitive pricing structures for entry of new pharmaceuticals and technology into crowded markets to gain market share advantages. He currently assists companies who are growing, restructuring, and transforming for the new market paradigms. Mr. McGinn is a licensed attorney in New York and Massachusetts, and also holds a Masters of Business Administration (MBA) in Strategy and Marketing from The McDonagh School of Business at Georgetown University in Washington, DC. He also holds a Joint Honors Bachelor of Laws in Law and Accounting fro
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 8, 2025. LUDWIG ENTERPRISES, INC. By: /s/ Scott J. Silverman Scott J. Silverman Chief Financial Officer 2